Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ubiquigent Announces £0.5M Funding

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Company also strengthens board of directors with key appointment.

Ubiquigent Limited has announced that it has received £0.5 million in funding from IP Group plc and the Scottish Investment Bank, the investment arm of Scottish Enterprise.

The investment will be used to accelerate the development and commercialization of these drug discovery platforms.

Ubiquigent has also announced an appointment to strengthen its board of directors. Joining the board as a Non-Executive Director, effective immediately, is Dr Mark Treherne.

Mark has been active in the pharmaceutical industry for over 25 years. In this time, he has been involved in starting and raising over £140 million for a number of early-stage biotechnology companies.

Amongst these, Mark was a co-founder and Chief Executive of Cambridge Drug Discovery, which was acquired by BioFocus plc. Mark has served on the boards of over 14 private and public biopharmaceutical companies in both executive and non-executive roles.

Located at the University of Dundee and with direct access to the leading scientific expertise of the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU), Ubiquigent develops and provides a range of reagents, kits, assay development, drug lead compound profiling (including DUBprofiler for profiling deubiquitylase enzyme inhibitors) and other services.

These products and services support academic and pharmaceutical researchers to understand the role of protein ubiquitylation in regulating many aspects of cellular functions and the development and optimization of drug candidate compounds that target the system addressing a number of critical therapeutic areas.

Ubiquigent already has a significant pharmaceutical and biotechnology client list and has delivered on a number of major high-throughput screening (HTS) assay development and compound profiling projects.

Involving the modification of proteins through the attachment of the protein ubiquitin, or ubiquitin-like proteins (Ubls), ubiquitylation and related Ubl modifications are key to the control of cellular protein homeostasis as well as signalling, akin to the critical role played by phosphorylation (approximately 20% of compounds in drug development target phosphorylation enzymes), and holds similar potential for clinical utility. The ubiquitin system offers many new drug discovery target opportunities across multiple therapeutic areas including oncology, neurodegeneration, cardiovascular and metabolic disorders.

The Company’s Scientific Advisory Board (SAB) is chaired by Professor Sir Philip Cohen, FRS, a world leading expert on the role of protein modifications in cellular regulation and the translation of this knowledge towards the treatment of human disease.

Also sitting on Ubiquigent’s SAB and contributing deep subject expertise are Professor Dario Alessi FRS (Director of the MRC-PPU) and Professor Ron Hay FRS.

Commenting on the funding Professor Cohen said: “The potential for developing drugs targeted at the ubiquitin system is very significant. The funding for Ubiquigent will ensure that novel capabilities are developed to enable ubiquitin-system drug discovery thus facilitating the addressing of new therapeutic targets across a wide range of disease areas.”

Dr Mark Treherne said: “I look forward to working closely with the Ubiquigent team to support the company in the planning and execution of its strategy in this high growth potential field. I also welcome the opportunity to work again alongside Professor Cohen with whom I had a very productive commercial collaboration in the past.”

Dr Jason Brown, Managing Director of Ubiquigent Ltd, added “We would like to thank IP Group plc and Scottish Enterprise for supporting the Company at this stage of its development. I look forward to working closely with Mark Treherne and other members of the management and Scientific Advisory Boards to lead the business through the next phase and deliver new approaches that help realize the full potential of this key area of drug discovery.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services
Ubiquigent has announced that it has significantly enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams to deliver an even more comprehensive range of services to the global life science research community.
Thursday, February 25, 2016
Ubiquigent, Cyclofluidic Enter Collaboration
This agreement combines ubiquitin focused biology expertise with proprietary chemistry platform to identify small molecule libraries that target the ubiquitin system.
Wednesday, June 03, 2015
Ubiquigent and University of Dundee Collaborate
Agreement brings together expertise to design, develop and market small molecule libraries targeting ubiquitin system proteins.
Wednesday, October 08, 2014
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!